Venture-capital investment in the biotechnology sector has proved to be resilient so far this year, despite stock-market turbulence and the slower pace of initial public offerings.

Alto Neuroscience wants to use EEG brain biomarkers to better match the right treatment to a person’s needs.

Entasis, which focuses on developing new antibacterial drugs to treat pathogens, utilizes a precision medicine approach to design specific drugs to target specific bacteria.

BlueSphere Bio’s CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why.

Ring Therapeutics was launched to take advantage of the viral residents of our bodies – the vast majority of which are anelloviruses. 

The FDA has lifted theclinical hold on Selecta Biosciences’ gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. The company is now back in the saddle as it preps for a phase 1 trial. 

France-based biologics company Valneva will be advancing toward U.S. Food and Drug Administration accelerated approval of its specialty vaccine, VLA1553. The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.

 To combat the problem of antifungal resistance, Scynexis developed an entirely new class of fungicide: triterpenoid antifungal, which doctors can prescribe when first-line azole treatments don’t work.